Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society’s Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago.

The presentation will highlight the pharmacologic profile of SEP-479, a potent, selective small molecule PTH1R agonist being developed for the treatment of hypoparathyroidism, including robust in vitro and in vivo activity supporting its potential as an oral therapy. SEP-479 is currently being evaluated in an ongoing Phase 1 single-ascending dose and multiple-ascending dose study in healthy volunteers, with data expected in late 2026 or early 2027.

“SEP-479 highlights the ability of our Native Complex Platform to discover novel oral small molecules directed towards challenging GPCR targets,” said Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna. “The preclinical data that will be presented at ENDO further characterize SEP-479 and support its potential to functionally replace PTH with a once-daily oral therapy. We believe this approach has the potential to redefine the treatment landscape for patients with hypoparathyroidism, and we look forward to further evaluating SEP-479 in the clinic as we advance our ongoing Phase 1 study.”

Presentation Details:

Title: Characterization of SEP-479, a Novel Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Abstract Number: ORF16-05
Session: Parathyroid Disease – Bone and Mineral Metabolism-02
Presenter: Jun Zhang, Ph.D., Senior Director of Translational Biology
Session Date and Time: June 13, 2026, 2:15-2:30 p.m. CT
Location: McCormick Place West, Room W187

About SEP-479

Septerna is developing SEP-479, a potent oral small molecule parathyroid hormone 1 receptor (PTH1R) agonist, for the treatment of patients with hypoparathyroidism. In preclinical studies, SEP-479 demonstrated activity comparable to PTH peptides in cell-based assays and in vivo models, normalized serum calcium in a rat model of hypoparathyroidism and increased serum calcium with reductions in endogenous PTH in a non-human primate PK/PD study. SEP-479 was generally well tolerated in 28-day GLP toxicology studies in rats, dogs and non-human primates.

Schreibe Deinen Kommentar